Clinical Trial

RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 18, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study examines the effect of the ultra long acting beta agonist/corticosteroid bronchodilator combination fluticasone furoate/vilanterol trifenatate, on respiratory muscles and ventilation in adults with severe bronchitis or emphysema (COPD).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2016-12-07; most recent amendment 2025-02-17.
Status change: Recruiting → Active, Not Recruiting 2021-06-20
Trial Details
NCT Number NCT02989935
Lead Sponsor University of Calgary
Conditions Copd
Enrollment 30 participants
Start Date 2016-04
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-18